May 2, 2024
BridgeBio Secures $200 Million from Venture Capitalists to Propel Oncology Spinout Beyond KRAS Class
BridgeBio, venture capital, oncology, spinout, KRAS class, cancer treatment, biotechnology, drug development, investment, healthcare.
Moderna Terminates Gene Editing Partnership, Shifts Focus to mRNA Technology
Moderna, Metagenomi, gene editing, partnership, mRNA technology, biotechnology, biobucks, deal termination
Moderna Maintains Long-Term Vision, Terminates Collaboration with Metagenomi
Moderna, first-quarter update, long-term strategy, Metagenomi, collaboration termination
Ingrezza, a Neurocrine Biosciences Drug, Receives FDA Approval for Tardive Dyskinesia Treatment
Neurocrine Biosciences, Ingrezza, FDA approval, tardive dyskinesia, neuropsychiatric disorder, valbenazine, first-of-its-kind treatment.
Amwell Reports Mixed Q1 Results with Decreased Sales but Narrowed Net Loss
Amwell, Q1 results, sales, net loss, telehealth, digital healthcare